advaxis inc american company devoted discovery development commercialization immunotherapies based technology platform uses engineered listeria monocytogenes aka company headquartered princeton new jersey incorporated delaware lmbased platform companys products based involves use attenuated lm secrete antigenadjuvant fusion proteins stimulate patients immune system specifically cells mount immune response secreted antigen antigen specifically found cancerous cells result aims effective immune response targeting eliminating treatments developed using paradigm referred lmllo today company fifteen distinct constructs various stages development directly developed company strategic collaborations centers national cancer institute cancer research uk wistar institute university pennsylvania department homeland security among others company also veterinary medicine program evaluating lmllo based immunotherapy phase study canine osteosarcoma source wwwadvaxiscom advaxis delaware corporation acquired shell corporation official sec november acquiring company great expectations incorporated colorado june operating company owned great expectations advaxis month acquisition changed name advaxis months reincorporated delaware official date inception company march advaxis entered codevelopment commercialization agreement indias biocon adxshpv therapeutic indian market addressing hpvassociated cancers including cervical advaxis immunotherapies based novel platform technology using live attenuated listeria monocytogenes lm bioengineered secrete antigenadjuvant fusion protein vectors infect key elements immune system secreted antigenadjuvant fusion protein redirects powerful immune response human beings inherit lm cancer adjuvant also reduces cancers defense immune attack adxshpv phase trials hpvassociated diseases cervical intraepithelial neoplasia cin cervical cancer hpvassociated head neck cancer advaxis published results first phase trial first lmllo based immunotherapy adxshpv vaccine june volume issue study assessed side effects associated increasing doses adxshpv patients metastatic refractory recurrent cervical cancer vaccine june volume issue httpsenwikipediaorgwikiadvaxis